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OBJECTIVE — Over half of newly diagnosed obese African Americans with diabetic ketoac-
idosis (DKA) discontinue insulin therapy and go through a period of near-normoglycemia
remission. This subtype of diabetes is known as ketosis-prone type 2 diabetes (KPDM).
RESEARCH DESIGN AND METHODS — To investigate the role of lipotoxicity on
-cell function, eight obese African Americans with KPDM, eight obese subjects with type 2
diabetes with severe hyperglycemia without ketosis (ketosis-resistant type 2 diabetes), and nine
nondiabetic obese control subjects underwent intravenous infusion of 20% intralipid at 40 ml/h
for48h.-CellfunctionwasassessedbychangesininsulinandC-peptideconcentrationduring
infusions and by changes in acute insulin response to arginine stimulation (AIRarg) before and
after lipid infusion.
RESULTS — The mean time to discontinue insulin therapy was 11.0  8.0 weeks in KPDM
and 9.6  2.2 weeks in ketosis-resistant type 2 diabetes (P  NS). At remission, KPDM and
ketosis-resistant type 2 diabetes had similar glucose (94  14 vs. 109  20 mg/dl), A1C (5.7 
0.4 vs. 6.3  1.1%), and baseline AIRarg response (34.8  30 vs. 64  69 U/ml). P  NS
despite a fourfold increase in free fatty acid (FFA) levels (0.4  0.3 to 1.8  1.1 mmol/l, P 
0.01) during the 48-h intralipid infusion; the response to AIRarg stimulation, as well as changes
in insulin and C-peptide levels, were similar among obese patients with KPDM, patients with
ketosis-resistant type 2 diabetes, and nondiabetic control subjects.
CONCLUSIONS — Near-normoglycemia remission in obese African American patients
withKPDMandketosis-resistanttype2diabetesisassociatedwitharemarkablerecoveryinbasal
and stimulated insulin secretion. A high FFA level by intralipid infusion for 48 h was not
associated with -cell decompensation (lipotoxicity) in KPDM patients.
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M
ore than half of newly diagnosed
African American patients pre-
senting with unprovoked diabetic
ketoacidosis (DKA) are obese (1,2). In
contrast to the chronic insulin depen-
dence of type 1 diabetic patients with ke-
toacidosis, most obese African American
patients with DKA display clinical and
metabolic features of type 2 diabetes dur-
ing follow-up (2–5). We and others have
reported that at presentation, obese Afri-
can American patients with DKA have
greater insulin secretion than lean type 1
diabetic patients with DKA but signiﬁ-
cantly lower than in obese type 2 diabetic
patients with hyperglycemia (no ketoaci-
dosis)(1,4,6).Insuchpatients,aggressive
diabetic management results in signiﬁ-
cant improvement in -cell function suf-
ﬁcient to allow discontinuation of insulin
therapy and go through a period of near-
normoglycemia remission, which may
last for a few months to several years
(4,6–8). A recent longitudinal study (6)
reported that after 10 years after diabetes
onset,40%ofpatientswithKPDMarestill
insulinindependent.Thisclinicalpresen-
tation is commonly reported in Africans
andinblackindividualsintheU.S.,butis
also observed in Native American, Japa-
nese, Chinese, Hispanic, and Caucasian
populations (2,3). Because of the mixed
featuresoftype1andtype2diabetes,this
variant of type 2 diabetes has been re-
ferred to in the literature as diabetes type
1B, atypical diabetes, diabetes type 1 1⁄2,
Flatbush diabetes, and, more recently, as
ketosis-prone type 2 diabetes (KPDM).
The underlying mechanism for the
transient insulin deﬁciency leading to se-
vere hyperglycemia ketoacidosis in Afri-
can Americans with KPDM is not known.
We hypothesized that obese African
AmericanswithKPDM,ascomparedwith
those with hyperglycemia (without keto-
sis) and obese control subjects, will prove
particularly susceptible to desensitization
of -cells due to sustained elevations in
free fatty acid (FFA) levels or -cell lipo-
toxicity. To test this hypothesis, a group
of obese African Americans with KPDM
and obese subjects with severe hypergly-
cemia (ketosis-resistant type 2 diabetes)
underwent a 48-h infusion of 20% in-
tralipid at 40 ml/h in order to increase
FFA levels approximately fourfold from
baseline at near-normoglycemia remis-
sion (1 week of discontinuation of in-
sulin therapy).
RESEARCH DESIGN AND
METHODS— A group of eight newly
diagnosed obese (BMI 30 kg/m
2) Afri-
can American patients with a history of
unprovoked DKA, eight patients with
type 2 diabetes with severe hyperglyce-
mia but without ketoacidosis, and nine
obesenondiabeticcontrolsubjectspartic-
ipatedinthisstudy.ThediagnosisofDKA
was established by a plasma glucose level
250 mg/dl (13.8 mmol/l), a serum bi-
carbonate18mmol/l,abloodpH7.3,
and a serum -hydroxybutyrate level 3
mmol/l (9). The obese type 2 diabetic hy-
perglycemicgroupincludedpatientswith
recently diagnosed diabetes who pre-
sented with glucose 400 mg/dl but
without ketosis. The control nondiabetic
group included obese subjects, matched
for age and BMI, with a fasting glucose
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mg/dl during a (75-g) oral glucose toler-
ancetest.Thisstudywasconductedatthe
clinical research unit at Grady Memorial
Hospital, Atlanta, Georgia, and was ap-
proved by the Emory University Institu-
tional Review Board.
At presentation, diabetic patients
with DKA and hyperglycemia were
treated with a low-dose intravenous insu-
lin infusion protocol (1,2). After resolu-
tion of ketoacidosis and/or hyper-
glycemia, patients were treated with NPH
and regular insulin twice daily at a start-
ing dose of 0.8 units/kg body wt. The in-
sulin dose was adjusted to achieve a
fasting and premeal glucose level 130
mg/dl. At discharge, patients were fol-
lowed at the outpatient Grady diabetes
clinic every 2–4 weeks for the ﬁrst 2
months, then every 2 months. Total insu-
lin dose was tapered after blood glucose
remained within targeted levels for 2–4
weeks or sooner if a patient experienced
hypoglycemia (70 mg/dl).
Experimental procedures
Participants were admitted to the Grady
Hospital General Clinical Research Cen-
ter,inrandomorder,ontwooccasionsfor
a 48-h infusion of intralipid and saline 1
week after discontinuation of insulin
therapy. After an overnight fast, an intra-
venous catheter was placed in each fore-
arm, one for infusion and one for blood
sampling. Subjects received a 48-h infu-
sion of intralipid (20%) at 40 ml/h. The
20% intralipid long-chain triglyceride
emulsion is composed of linoleic acid
(50% oleic acid; 26% palmitic acid; 10%
stearic acid; 9% egg yolk; 3.5% phos-
pholipids).
Sequential arginine stimulation tests
To assess the baseline insulin secretion
and glucose-potentiating effect, sequen-
tial arginine stimulation tests (10) were
performedatbaselineplasmaglucoseand
following an infusion of 10% dextrose
with 5 mEq/l of KCl at 200 mg/m
2 per
min for 45 min using a peristaltic pump.
A maximally stimulatory dose of 10% ar-
ginine (5 g) was injected at each time as a
bolus over a period of 30 s, and blood
samples were drawn at 30, 0, and 2, 3,
4, 5, 7, 15, and 30 min for measurement
of glucose, insulin, and C-peptide levels.
Acute insulin response to arginine
(AIRarg) was deﬁned as the difference be-
tween basal and the mean insulin values
at 2, 4, and 5 min following each arginine
pulse. Sequential arginine stimulation
was performed at baseline prior to and at
the end of the 48-h intralipid and saline
infusion.
Forty-eight–hour intralipid infusion
protocol
Following the initial arginine stimulation
test, subjects received a 48-h infusion of
intralipid (20%) at 40 ml/h. Blood sam-
ples were drawn on admission for glu-
cose, insulin, C-peptide, and FFAs.
During the infusion, glucose was mea-
sured every2ha tt h ebedside using a
glucose meter, and blood samples were
drawn every 4 h for laboratory assays in-
cluding glucose, insulin, C-peptide, and
FFAs. During the study period, subjects
consumed a 2,000-calorie diet/day con-
sisting of 20% of calories derived from
protein, 30% from fat, and 50% from car-
bohydrate. Lipid and saline infusion was
started at 12 noon (Fig. 1) and contin-
ued for 48 h.
Laboratory methods
Plasma glucose was measured using the
glucose oxidase method. Levels of insulin
and C-peptide were measured in plasma
using a solid-phase, two-site sequential
chemiluminescent immunometric assay
on the DPC Immulite analyzer (Diagnos-
tic Products Corporation, Los Angeles,
CA). The instrument calibrations for the
assays were performed as recommended
bythemanufacturersandwerewithinthe
speciﬁcations.
Figure1—Argininestimulationtestsperformedpriortoandfollowinga48-hintralipidinfusioninobesesubjectswithKPDM,obesetype2diabetic
subjects with hyperglycemia (ketosis resistant), and obese nondiabetic control subjects. A maximally stimulatory dose of 10% arginine (5 g) was
injected at baseline plasma glucose and following an infusion of 10% dextrose with 5 mEq/l of KCl at 200 mg/m
2 per minute for 45 min. Values are
means  SE. F, KPDM; E, hyperglycemia;  , control.
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AlldatainthetextandTable1areexpressed
asmeansSD,andthedataintheﬁgures
are expressed as means  SE. Compari-
sons among the nondiabetic control
group, KPDM group, and obese diabetic
group with hyperglycemia were con-
ducted using nonparametric Kruskal-
Wallis for continuous variables and using
the Fisher’s exact test for categorical vari-
ables. With infusion data, repeated-
measures analyses were carried out to
assess the group difference simulta-
neously with the change over time in
FFAs, blood glucose, insulin, C-peptide,
and the C-peptide–to–glucose ratio (1).
Statistical signiﬁcance was deﬁned as P 
0.05. Statistical analysis was performed
using the SAS version 9.2.
RESULTS
Patient characteristics
The clinical characteristics of patients
withKPDM,hyperglycemiawithoutketo-
sis, and nondiabetic control subjects are
shown in Table 1. All patients were Afri-
can American, obese, had recently diag-
nosed diabetes, and were mostly male
with a strong family history of diabetes.
On admission, KPDM patients had a
mean blood glucose level of 891  282
mg/dl, a serum bicarbonate of 14  4
mEq/l, a venous pH of 7.19  0.24, an
anion gap of 23  7 mEq/l, and a -hy-
droxybutyrate level 3.0 mmol/l. Keto-
sis-resistant type 2 diabetic patients with
hyperglycemiahadabloodglucoseonad-
mission of 537  140 mg/dl, a serum bi-
carbonate of 23  3 mEq/l, venous pH
7.36  0.04, anion gap 14  7 mEq/l,
and -hydroxybutyrate 3.0 mmol/l.
Obese nondiabetic control subjects had a
mean fasting blood glucose of 88  9
mg/dl. Admission levels of A1C were
12.1%inKPDMand13%inobesehyper-
glycemic subjects.
The mean time to achieve remission
andinsulindiscontinuationinobeseKPDM
subjects was 11  8 and 9.6  2.2 weeks
in obese patients with hyperglycemia (P 
NS).Atremission,KPDMandtype2diabe-
tes had similar glucose (94  14 vs. 109 
20 mg/dl) and hemoglobin A1C (5.7 0.4
vs. 6.3  1.1%) levels, respectively.
Sequential arginine stimulation tests
Changes in insulin concentration during
sequential arginine stimulation tests at
baseline and after dextrose infusion prior
to and after the 48-h intralipid infusion
are shown in Fig. 1A and B, respectively.
From these values, the AIRarg (difference
between basal and the mean insulin val-
ues at 2, 3, 4, and 5 min) was calculated
before and after the 48-h intralipid infu-
sion. At baseline, starting at a mean glu-
cose concentration of 113  20 mg/dl in
obese hyperglycemia and 96  13 mg/dl
in KPDM, the baseline AIRarg response in
obesetype2diabeticsubjectswithhyper-
glycemia (64  69 U/ml) was higher
but not signiﬁcantly different from that
in obese KPDM subjects (34.8  30.3
U/ml). Nondiabetic control subjects
had a baseline blood glucose of 91  12
mg/dl and an AIRarg of 44  51 U/ml.
The P value for blood glucose difference
among these three groups is 0.004, and
the P value for AIRarg difference is 0.857.
Following the basal arginine test, subjects
received the administration of dextrose
infusion (200 mg   kg
1   min
1) for 45
min followed by a second pulse of argi-
nine. Dextrose infusion resulted in a fur-
ther increase in insulin secretion (glucose
potentiating effect) in diabetic and con-
trol subjects. With a mean basal blood
glucose of 163  32 mg/dl in KPDM,
172  55 mg/dl in obese hyperglycemia,
and 172  23 in obese control subjects,
we also observed a higher AIRarg in obese
hyperglycemic subjects (178  204
U/ml), but results were not signiﬁcantly
different from those observed in obese
KPDM (98  107 U/ml) or nondiabetic
control subjects (163  138 U/ml).
To assess the impact of intralipid in-
fusion on insulin secretion, a repeated ar-
ginine stimulation test was performed
within1ho fcompleting the 48-h in-
tralipidinfusion.Ofinterest,weobserved
no signiﬁcant differences in AIRarg be-
tween the two diabetic groups and in
nondiabetic subjects, and all groups
maintained the glucose-potentiating ef-
fect during arginine stimulations (Fig.
1B). KPDM patients had a baseline mean
blood glucose concentration of 116  31
mg/dl and an AIRarg of 33  55 U/ml
compared with patients with hyperglyce-
mia who had a baseline mean blood glu-
cose of 132  29 mg/dl and an AIRarg of
115  120 U/ml after lipid infusion
(P  0.159). Nondiabetic control sub-
jectshadabaselinemeanbloodglucoseof
99  15 mg/dl and an AIRarg of 21  71
U/ml. Dextrose infusion for 45 min re-
sulted in a further increase in arginine-
stimulated insulin secretion, with an
AIRarg of 150  168 U/ml in KPDM,
183  168 U/ml in hyperglycemic sub-
jects,and11390U/mlinnondiabetic
control subjects. There were no signiﬁ-
cant differences in change of insulin area
underthecurve(AUC)orglucoseAUCin
response to sequential argninine stimula-
tion from baseline among three groups.
Plasma FFAs, glucose, C-peptide,
and C-peptide–to–glucose ratio
during intralipid infusion
Intralipid infusion resulted in rapid and
sustained elevations of FFA levels from
Table 1—Clinical features of subjects with KPDM, ketosis-resistant type 2 diabetes with
hyperglycemia (ketosis resistant), and nondiabetic control subjects
KPDM
Ketosis
resistant
Nondiabetic
control subjects
n 88 9
Age (years) 39  10 48  94 0  7
Sex (male/female) (n) 6/2 6/2 2/7
Race (African Americans) (%) 8 (100) 8 (100) 9 (100)
Newly diagnosed diabetes (%) 8 (100) 8 (100) —
Family history of diabetes (%) 7 (88) 8 (100) 8 (89)
BMI (kg/m
2) 38  43 8  53 7  9
Positive GAD antibodies (%) 0 (0) 0 (0) —
A1C at presentation (%) 12.1  3 12.8  2—
Blood glucose at presentation (mg/dl) 891  282 537  140 88  9
Bicarbonate (mEq/l) 14  42 3  3—
pH 7.19  0.24 7.36  0.04 —
Anion gap (mEq/l) 23  71 4  7—
Time to insulin discontinuation
(remission) (weeks) 11.0  8.0 9.6  2.2 —
A1C at remission (%) 5.7  0.4 6.3  1.1 —
Blood glucose at remission (mg/dl) 94  14 109  20 —
Data are means  SD, unless otherwise indicated.
-Cell lipotoxicity in KPDM
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groups (Fig. 2A). From a fasting FFA of
0.4  0.3 mmol/l in diabetic subjects and
0.40.3mmol/lincontrolsubjects,FFA
levels increased to 1.5  1.1 mmol/l in
KPDM, 1.9  0.4 mmol/l in obese type 2
diabetes with hyperglycemia, and 1.8 
1.1 mmol/l in nondiabetic control sub-
jects at the end of intralipid infusion, re-
spectively (P  NS difference between
groups at baseline or during intralipid
infusion).
Compared with baseline levels,
changes in blood glucose values during
intralipid infusion (Fig. 2B) increased
frombaselineglucoselevelsof9414to
120  33 mg/dl in KPDM (P  0.012) at
the end of the intralipid infusion, from
109  20 to 136  35 mg/dl in obese
subjectswithhyperglycemia(P0.103),
and from 92  12 to 98  12 mg/dl (P 
0.266) in nondiabetic control subjects.
Meanbloodglucoseattheendofinfusion
was not signiﬁcantly different between
thetwodiabeticgroups.Duringintralipid
infusion, the AUC for glucose levels (as-
suming linear interpolation) were
5,204  1,222 in KPDM, 6,420  1,332
in type 2 diabetes with hyperglycemia,
and 5,230  436 in nondiabetic control
group. Analysis based on repeated-
measuresANOVAshowedthatbloodglu-
cose increased signiﬁcantly from baseline
attheendofinfusion(P0.002)andwas
signiﬁcantly different among groups (P 
0.019).
Intralipidinfusionfor48hresultedin
a sustained increase in C-peptide levels in
KPDMandhyperglycemicpatientsfroma
baselineof2.51.2and3.51.1ng/ml
toameanlevelof5.42.3and6.52.1
ng/ml at the end of the infusion, respec-
tively (both P  0.102 from baseline and
P  0.247 between the two diabetic
groups) (Fig. 2C). In nondiabetic control
subjects, C-peptide levels increased from
a baseline of 2.6  1.7 ng/ml to a mean of
3.9  2.4 ng/ml at the end of the infusion
(P  0.229). Insulin secretion estimated
by the C-peptide–to–glucose ratio (C-
peptide [ng/ml]/glucose [mg/dl] 	 100)
and by differences in AUC during in-
tralipid infusion (11). There were no sig-
niﬁcant differences in the C-peptide–to–
glucose ratio (Fig. 2D) or in the AUC for
C-peptide, insulin, and C-peptide–to–
glucose ratio during the 48-h intralipid
infusion. Repeated-measures analyses re-
vealed no differences in FFAs, C-peptide,
or C-peptide–to–glucose ratio among
KPDM, obese subjects with hyperglyce-
mia, and nondiabetic control subjects al-
though there were signiﬁcant increases
Figure2—Changesinplasmafreefattyacids(A),plasmaglucose(B),andC-peptide(C)andC-peptide–to–glucoseratio(D)during48-hintralipid
infusion in obese subjects with KPDM, type 2 diabetic subjects with hyperglycemia, and obese nondiabetic control subjects. Values are means  SE.
F, KPDM; E, hyperglycemia;  , control.
Umpierrez and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 629from baseline. These results indicate that
increased FFAs during intralipid infusion
for 48 h were not associated with im-
paired insulin secretion or -cell lipotox-
icityinobesesubjectswithKPDMorwith
a history of hyperglycemia without
ketoacidosis.
CONCLUSIONS — Over half of adult
subjects with recently diagnosed diabetes
presenting with DKA display clinical,
metabolic, and immunological features of
type 2 diabetes, including a high rate of
obesity, a strong family history of diabe-
tes, a low prevalence of autoimmune
markers, and lack of HLA genetic associ-
ation(2,3).Manyofsuchpatientsdiscon-
tinueinsulintherapywithinafewmonths
oftreatmentandremainingoodglycemic
control with diet and/or oral antidiabetic
therapy for several years (1,2,4,6). Meta-
bolic studies have evidenced insulin
secretiondeﬁciencyasthemajordetermi-
nant of metabolic decompensation in
KPDM patients. We previously reported
that intravenous glucose infusion shortly
after resolution of DKA did not evoke any
insulin response; however, improvement
of metabolic control resulted in threefold
higher insulin levels at near-normoglyce-
mia remission (1,5). Changes in C-
peptide response after a mixed meal or
glucagon stimulation have been shown to
be intermediate between lean type 1 dia-
betic patients with DKA and obese hyper-
glycemic patients with type 2 diabetes
(1,5–7). The subsequent remission is due
to a restoration, at least partial, of the
-cell insulin secretory capacity after
achievement of good metabolic control
(6,8). KPDM patients who achieved re-
mission experienced an 80% improve-
ment in fasting and stimulated C-peptide
levels, whereas those who did not achieve
remission lost 60% of their insulin secre-
tory capacity (6). These ﬁndings indicate
that the impaired -cell function in
KPDM patients cannot be attributed to an
irreversible-celldamagebuttotransient
functional abnormalities of the -cells.
Clinical and experimental data indi-
cate that increased FFAs may contribute
to the development of peripheral insulin
resistance and type 2 diabetes (12). In ad-
dition to inhibiting insulin action, recent
evidence indicates that FFAs have an im-
portant role in the regulation of -cell
function (13). In vitro and animal studies
have shown that prolonged exposure of
rat (14) and human (15) islets to fatty ac-
ids decreases glucose-stimulated insulin
secretion. In addition, FFAs inhibit insu-
lin gene expression (15,16), in part via
negative regulation of the transcription
factorpancreaticduodenumhomeobox-1
(17). FFAs may also reduce efﬁciency of
proinsulin to insulin conversion within the
-cells(14)andmayimpairpotassiumATP
channel–dependent and potassium ATP
channel–independent pathways of insulin
secretion (14). In humans, sustained
(24–48 h) elevation of FFAs may decrease
glucose-stimulated insulin secretion in
nondiabetic individuals (12,18,19). Ac-
cordingly,wehypothesizedthat-celllipo-
toxicity may explain the metabolic
decompensation in obese African Ameri-
canswithKPDMandthatsuchpatientswill
be more susceptible to FFA-induced -cell
dysfunction than obese patients with keto-
sis-resistant type 2 diabetes and obese non-
diabetic control subjects.
Totestthelipotoxicityhypothesis,we
assessed -cell function by changes in
AIRargbothatbaselineandduringglucose
infusion before and after the 48-h in-
tralipidinfusionandbychangesininsulin
and C-peptide concentration during lipid
infusion. The concentrations of FFAs
achieved during intralipid infusion (Fig.
2A)weresimilartothelevelsofFFAspre-
viouslyreportedinketosis-pronediabetic
patients at presentation with DKA (20).
Among the single amino acids known to
stimulate insulin secretion in humans, ar-
ginine is the most potent (21). Arginine
plus glucose, given intravenously, have
been shown to act synergistically on insu-
lin secretion resulting in a greater rise of
serum insulin than the sum of the re-
sponse to separate infusions of glucose
andarginine(10,21).Thehyperglycemic
potentiating effect of insulin response
to arginine is a sensitive indicator of
pancreatic insulin secretory capacity
(21,22). Despite a recent history of se-
vere hyperglycemia and ketoacidosis,
KPDM patients exhibit an appropriate
glucose-potentiating effect indicating a
remarkable recovery of insulin secretion
duringremission.Serumconcentrationof
C-peptide and insulin were similar be-
tween groups during the 48-h intralipid
infusion, and the glucose-potentiating ef-
fect of arginine in KPDM patients was
similar to that observed in type 2 diabetic
patients and to nondiabetic control sub-
jects. These results allow us to conclude
that short-term high FFA levels are not a
primary pathophysiologic factor in the
developmentof-celldecompensationin
KPDM patients.
We acknowledge the following limi-
tations in this study. The duration of in-
tralipid infusion in our study was limited
to 48 h. Kashyap et al. (12) reported that
a 4-day lipid infusion in subjects at high-
risk of developing type 2 diabetes impairs
insulin secretion in response to mixed
meals and to intravenous glucose. The
lack of short-term lipotoxicity could also
be explained by the fact that we studied
patients after remission under the near-
normoglycemia state. Previous studies
have shown that high fat administration
impairs insulin secretion only in the con-
text of chronic hyperglycemia (23).
Briaudetal.(24)reportedthatantecedent
hyperglycemia, not plasma lipid levels,
lead to high islet triacylglycerol content
and decreased insulin gene expression
and that both hyperlipidemia and hyper-
glycemia must be present simultaneously
for FFAs to affect -cell function (24). In
addition, we did not measure C-peptide
levels during sequential arginine stimula-
tion tests in order to estimate changes in
insulin clearance. Finally, intralipid
emulsion is a soybean oil–based lipid
emulsion rich in omega-6 polyunsatu-
rated fatty acids (25) that are different
from human dietary intake. It is not
knownifcomparableincreasesinFFAsby
repeated oral fat load can impair insulin
secretion in obese subjects with KPDM
and type 2 diabetes.
In summary, our studies indicate that
KPDM represents a subset of type 2 dia-
betes and that the near-normoglycemia
remission phase is associated with a re-
markable recovery in insulin secretion.
Despite a recent history of severe hyper-
glycemia and ketoacidosis, at remission,
KPDM patients have similar basal and
stimulated insulin secretion than subjects
withnonketotichyperglycemiaandobese
nondiabetic control subjects. In addition,
our study indicates that despite a fourfold
increase in FFA levels, basal and stimu-
lated insulin secretion was preserved,
suggesting that short-term high FFA lev-
els are not a primary pathophysiologic
factor in the development of -cell de-
compensation in KPDM patients.
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